A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).

Authors: Hans Gelderblom, Emanuela Palmerini, Jean-Yves Blay, Michiel van de Sande, Javier Martin Broto, Raul Terés, Madhu Davies, Elyse Seltzer, Sander Veltkamp, Gabriel Tinoco

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps11584

Source: Full article

---

Abstract

TPS11584